[{"data":1,"prerenderedAt":102},["ShallowReactive",2],{"ki-studienmonitor-study-2026-525620-23-00":3},{"id":4,"euct":5,"title":6,"publicTitle":6,"fullTitle":7,"shortTitle":8,"status":9,"statusCode":10,"startDateEU":11,"decisionDate":12,"publishDate":13,"trialRegion":14,"trialRegionCode":15,"medicalConditions":16,"therapeuticAreas":20,"trialCategory":27,"duration":28,"countries":31,"applications":51,"evidence":65,"official":71,"slug":5,"firstObservedAt":74,"lastObservedAt":75,"dateModified":76,"materialFingerprint":77,"events":78},"ctis:2026-525620-23-00","2026-525620-23-00","Local and Systemic Immune Modulation by Rilvegostomig in Advanced Gastric Cancer: The RILVE Project","Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)","VHIO26001\u002FESR2523009","Authorised","2",null,"2026-07-22T10:55:01.733","2026-07-29T03:42:06.995509076","Both","3",[17],{"name":18,"rareDisease":19},"advanced gastric cancer",false,[21,24],{"code":22,"name":23},"6","Diseases [C] - Digestive System Diseases [C06]",{"code":25,"name":26},"4","Diseases [C] - Neoplasms [C04]",{"phaseCode":25,"categoryCode":10,"lowIntervention":19},{"estimatedRecruitmentStartDate":29,"estimatedEndDate":30,"estimatedGlobalEndDate":30},"2026-06-01","2030-06-01",[32],{"name":33,"publicStatusCode":10,"firstDecisionDate":12,"lastDecisionDate":12,"history":34},"Spain",[35,43,47],{"source":36,"applicationBusinessKey":37,"applicationType":38,"status":9,"trialStatus":9,"decision":39,"assessmentOutcome":40,"assessmentOutcomeDate":41,"date":42,"reportingStatusCode":9,"applicationStatusCode":9},"application_country_status","IN","INITIAL","authorized","acceptable","2026-07-20","2026-07-22",{"source":44,"applicationBusinessKey":37,"applicationType":38,"status":9,"trialStatus":9,"decision":39,"assessmentOutcome":40,"eventType":45,"date":12,"isRMS":46},"application_decision","decision",true,{"source":44,"applicationBusinessKey":48,"applicationType":49,"status":9,"trialStatus":9,"decision":39,"assessmentOutcome":11,"eventType":45,"date":50,"isRMS":46},"NSM-1","NON SUBSTANTIAL MODIFICATION","2026-07-28T13:12:22.067",[52,59],{"id":53,"businessKey":37,"type":38,"status":9,"trialStatus":9,"submissionDate":54,"decisionDate":42,"decisions":55,"countryStatuses":57},"application:2026-525620-23-00:in","2026-04-30",[56],{"mscName":33,"decisionDate":12,"decision":39,"assessmentOutcome":40,"eventType":45,"applicationType":38,"isRMS":46},[58],{"countryName":33,"mscName":33,"trialStatus":9,"decision":39,"decisionDate":42,"firstDecisionDate":42,"assessmentOutcome":40,"assessmentOutcomeDate":41,"reportingStatusCode":9,"applicationStatusCode":9},{"id":60,"businessKey":48,"type":49,"status":9,"trialStatus":9,"submissionDate":61,"decisionDate":61,"decisions":62,"countryStatuses":64},"application:2026-525620-23-00:nsm-1","2026-07-28",[63],{"mscName":33,"decisionDate":50,"decision":39,"assessmentOutcome":11,"eventType":45,"applicationType":49,"isRMS":46},[],[66],{"id":67,"path":68,"term":69,"snippet":70},"evidence:c9c51035d7df7913aec02ce5","authorizedApplication.authorizedPartI.trialDetails.trialInformation.endPoint.secondaryEndPoints[4].endPoint","artificial intelligence","…expression and\u002For spatial distribution in the tumor microenvironment (eg, CD8, PD-L1, etc.) as measured by IHC and other assays including analytical methods (eg, digital pathology artificial intelligence).",{"retrieveUrl":72,"publicUrl":73},"https:\u002F\u002Feuclinicaltrials.eu\u002Fctis-public-api\u002Fretrieve\u002F2026-525620-23-00","https:\u002F\u002Feuclinicaltrials.eu\u002Fctis-public\u002Fview\u002F2026-525620-23-00?lang=en","2026-07-23T11:19:41.794Z","2026-08-12T02:29:00.000Z","2026-08-12","4dca8fb1e9ab0040a140f540740fddb0dcd92c20ebd207a50a56d706d9b887f4",[79,83,86,89,92,94,96,98],{"id":80,"studyId":4,"euct":5,"type":81,"date":54,"timeBasis":82,"applicationBusinessKey":37,"country":11,"status":9,"trialStatus":9,"decision":11,"assessmentOutcome":11},"event:b26f994fd1d0c9f5cd6d29f0","application_submitted","official_record_date",{"id":84,"studyId":4,"euct":5,"type":85,"date":41,"timeBasis":82,"applicationBusinessKey":37,"country":33,"status":9,"trialStatus":9,"decision":39,"assessmentOutcome":40},"event:77dcc198c36f736adc742939","country_assessment",{"id":87,"studyId":4,"euct":5,"type":88,"date":42,"timeBasis":82,"applicationBusinessKey":37,"country":11,"status":9,"trialStatus":9,"decision":11,"assessmentOutcome":11},"event:0737a61c1bf424872ba3f48d","application_status",{"id":90,"studyId":4,"euct":5,"type":91,"date":12,"timeBasis":82,"applicationBusinessKey":37,"country":33,"status":9,"trialStatus":9,"decision":39,"assessmentOutcome":40},"event:fb256348fa07584c386db38f","country_decision",{"id":93,"studyId":4,"euct":5,"type":81,"date":61,"timeBasis":82,"applicationBusinessKey":48,"country":11,"status":9,"trialStatus":9,"decision":11,"assessmentOutcome":11},"event:0701670ff4ebcbec51ba605c",{"id":95,"studyId":4,"euct":5,"type":88,"date":61,"timeBasis":82,"applicationBusinessKey":48,"country":11,"status":9,"trialStatus":9,"decision":11,"assessmentOutcome":11},"event:0efaeb6c6e52aa198ad60cda",{"id":97,"studyId":4,"euct":5,"type":91,"date":50,"timeBasis":82,"applicationBusinessKey":48,"country":33,"status":9,"trialStatus":9,"decision":39,"assessmentOutcome":11},"event:a3a5d0e2e0a9fd29e8e29465",{"id":99,"studyId":4,"euct":5,"type":100,"date":75,"timeBasis":101,"applicationBusinessKey":11,"country":11,"status":9,"trialStatus":9,"decision":11,"assessmentOutcome":11},"event:9650edf977bf66018f52af54","trial_status_observed","collector_observation",1786545326512]